Streetbeat News

Regulatory

SRRK

Scholar Rock (NASDAQ:SRRK) announced new preclinical data for SRK-439, showing potential benefits for healthy weight loss by preserving lean mass and improving fat mass loss. The data, presented at the Keystone Symposia, demonstrated SRK-439's effectiveness in combination with GLP-1 receptor agonists in diet-induced obesity mice. SRK-439, a novel myostatin inhibitor, also showed incremental lowering of fasting glucose levels. Scholar Rock plans to initiate a proof-of-concept study with apitegromab in obesity, with trial initiation expected in mid-2024.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 1:15 pm

RVPH

Reviva Pharmaceuticals Holdings, Inc. (RVPH) announced a KOL event on February 15, 2024, to discuss Phase 3 RECOVER trial results of brilaroxazine for schizophrenia. The event will feature experts Larry Ereshefsky and Mark Opler, focusing on the unmet medical need in schizophrenia treatment and brilaroxazine's potential. The trial showed positive outcomes, meeting all primary and secondary endpoints with a well-tolerated side effect profile. Brilaroxazine is also being developed for other neuropsychiatric and inflammatory diseases, having received Orphan Drug Designation for PAH and IPF.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 1:13 pm

ECOR

electroCore, Inc. (NASDAQ:ECOR), a bioelectronic medicine company, announced the issuance of U.S. Patent No. 11,894,148 for treating disorders associated with the Coronaviridae family (COVID) using electrical impulses. The patent covers methods of reducing C-reactive protein levels in the blood by applying electrical impulses to the vagus nerve.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 1:11 pm

BRTX

BioRestorative Therapies, Inc. (BRTX), a clinical stage company focusing on stem cell-based therapies, announced the exercise of existing warrants and issuance of new warrants in a private placement, aiming to raise approximately $8.1 million in gross proceeds. The transaction involves the exercise of warrants for 3,351,580 shares at a reduced price of $2.33 per share and the issuance of new warrants exercisable for 2,513,685 shares at $2.43 per share, with a five-year term. Roth Capital Partners is the financial advisor for this transaction. The company plans to file a resale registration statement on Form S-3 with the SEC within 10 days to register the resale of shares underlying the new warrants.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 1:09 pm

BSX

Boston Scientific Corporation (NYSE:BSX) received FDA approval for an expanded indication of its WaveWriter SCS Systems to treat chronic low back and leg pain in individuals without prior back surgery, known as non-surgical back pain (NSBP).

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 1:05 pm

MA

NovoPayment has partnered with Mastercard to expand its operations in Mexico through the Mastercard Network Enablement Partner program. This certification allows NovoPayment to process Mastercard transactions in Mexico, enhancing its multi-rail payments strategy and offering greater choice and flexibility to its clients. NovoPayment aims to leverage this partnership to expedite product innovation, reduce time to market, and improve operational efficiency.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 1:05 pm

INVZ

Innoviz Technologies has received the IATF 16949:2016 certification for its design and assembly of Lidar, Perception SW, and Lidar solutions, reinforcing its status as a reliable Tier-1 supplier.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 1:04 pm

IRIX

Iridex Corporation (NASDAQ:IRIX) announced the grant of a European Patent EP 3009093 for its MicroPulse technology, enhancing laser treatments in ophthalmology. This technology minimizes risks associated with traditional laser treatments and is exclusive to Iridex, reinforcing its position in the market.

Portfolio Pulse from Benzinga Newsdesk

February 06, 2024 | 1:03 pm

SPY

USO

VGK

Russia's Tuapse Oil Refinery, a significant facility, will not resume operations this month, according to sources cited by Reuters. This development could have implications for global oil supply and market dynamics.

Portfolio Pulse from Charles Gross

February 06, 2024 | 12:40 pm

JJSF

PLTR

QQQ

RMBS

SPY

U.S. stocks are expected to face another day of declines as the recent rally loses momentum, despite some positive tech earnings. Concerns about overbought levels and Federal Reserve's stance on interest rates have prompted caution. The S&P 500 and Dow Industrials retreated from record levels, with most sectors except healthcare experiencing declines. Analysts predict a potential pullback for the S&P 500, citing overbought conditions and negative divergence in market breadth. Premarket trading saw SPDR S&P 500 ETF Trust and Invesco QQQ ETF with minor adjustments. Several companies, including Rambus, Palantir Technologies, and J&J Snack Foods, moved significantly on earnings news.

Portfolio Pulse from Shanthi Rexaline

February 06, 2024 | 12:37 pm